Advagene Biopharma Co., Ltd. (TPEX: 6709)
Health Care · Pharmaceuticals · TW
NT$23.95
-0.21% today · -33.4% 1Y
Advagene Biopharma Co., Ltd. (TPEX: 6709) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $44.48M and employs 16 people.
Over the last twelve months the share price has lost 33.4%, trading between 22.50 and 37.35.
Tweenvest scores Advagene Biopharma Co., Ltd. across four factors: quality 37/100, value 42/100. Its strongest factor is value.
6709 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $44.48M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.52
- Dividend yield
- —
- Beta (5Y)
- 0.68
- 52-week high
- NT$37.35
- 52-week low
- NT$22.50
- Avg volume (3M)
- —
- Shares outstanding
- 59.38M
- Employees
- 16
- Next earnings
- —
About Advagene Biopharma Co., Ltd.
Based in Taipei, Taiwan, Advagene Biopharma Co., Ltd. is a firm dedicated to pioneering advancements in vaccine science and associated medical solutions. Its current development portfolio comprises a nasal spray vaccine for influenza, various allergy-specific vaccines, and an immunotherapy targeting COVID-19.
- ISIN
- TW0006709009
- Founded
- 2006
- Listed since
- Nov 29, 2018
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Trident Lifeline LimitedBSE: 543616 | $45.62M | Rs370.00 | -1.69% |
| Vext Science, Inc.CNSX: VEXT | $45.14M | CA$0.26 | +15.56% |
| Yuyu Pharma, Inc.KOSE: A000220 | $44.98M | ₩3,840.00 | +1.59% |
| Oncoinvent ASAOB: ONCIN | $44.84M | Nkr69.40 | -0.86% |
| Arovella Therapeutics LimitedASX: ALA | $43.87M | AU$0.05 | +10.64% |
| Grace Therapeutics, Inc.NasdaqCM: GRCE | $43.75M | $1.98 | -4.81% |
| Entropy Neurodynamics LimitedASX: EX1 | $43.32M | AU$— | — |
| Entropy Neurodynamics LimitedASX: ENP | $43.32M | AU$0.04 | -2.56% |
Figures last refreshed Oct 11, 2026.